Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejca.2021.03.033 http://scihub22266oqcxt.onion/10.1016/j.ejca.2021.03.033 33882374!7997727!33882374     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Cancer 2021 ; 150 (ä): 1-9 Nephropedia Template TP {{tp|p=33882374|t=2021. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients |pdf=|usr=}}{{33882374}} gab.com Text Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients JO: Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33882374 #FOAvip BACKGROUND: Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus. METHODS: We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients. RESULTS: In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients. CONCLUSION: Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs. Twit Text FOAVip Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients ????Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33882374 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33882374 #FOAvip English Wikipedia <ref>{{Cite pmid|33882374}}</ref> Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients #MMPMID33882374 Mansi L; Spehner L; Daguindau E; Bouiller K; Almotlak H; Stein U; Bouard A; Kim S; Klajer E; Jary M; Meynard G; Vienot A; Nardin C; Bazan F; Lepiller Q; Westeel V; Adotevi O; Borg C; Kroemer M Eur J Cancer 2021[Jun]; 150 (ä): 1-9 PMID33882374show ga BACKGROUND: Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus. METHODS: We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients. RESULTS: In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients. CONCLUSION: Given the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs. |Aged[MESH] |Antibodies, Viral/*immunology[MESH] |COVID-19/*immunology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Neoplasms/*complications[MESH] |SARS-CoV-2[MESH]Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-p(epmc).pdf DeepDyve Pubget Overpricing